Table 1 Clinicopathological characters of the enrolled patients (N = 38)
Parameters | N (%) |
|---|---|
Age (median (range)) | 53 (36–69) |
Grade | |
II | 28 (73.68) |
III | 10 (26.32) |
Subtypes | |
Luminal A | 6 (15.79) |
Luminal B HER-2 negative | 12 (31.58) |
Luminal B HER-2 positive | 7 (18.42) |
HER-2 positive | 9 (23.68) |
TNBC | 4 (10.53) |
Anatomical stage before neoadjuvant therapy | |
IIA | 6 (15.79) |
IIB | 24 (63.16) |
IIIA | 8 (21.05) |
Tumor histopathology | |
Ductal | 35 (92.11) |
lobular | 1 (2.63) |
Other type | 2 (5.26) |
Neoadjuvant systemic regimen | |
Chemotherapy | 24 (63.16) |
Chemotherapy and targeted therapy | 14 (36.84) |
Surgery | |
Breast-conserving therapy | 3 (7.89) |
MRM | 31 (81.58) |
MRM + Expander implantation | 4 (10.53) |
Interval from clip + carbon nanoparticles injection to operation (day), median (range) | 127 (1–203) |
Clinical response evaluation based on RECIST | |
Complete response | 5 (13.16) |
Partial response | 26 (68.42) |
Stable disease | 7 (18.42) |
Progression of disease | 0 (0) |
Miller-Payne grade system | |
G1-G2 | 18 (47.37) |
G3 | 9 (23.68) |
G4 | 6 (15.79) |
G5 | 5 (13.16) |
Residual cancer burden index | |
0 | 3 (7.89) |
I | 4 (10.53) |
II | 12 (31.58) |
III | 19 (50.00) |
Clipped node in SLNs | 29 (76.32) |
Distribution of residual node disease(N = 32) | |
TAD nodes only | 14 (43.75) |
TAD nodes + other axillary nodes | 16 (50.00) |
Other axillary nodes only | 2 (6.25) |